Search results
Results from the WOW.Com Content Network
Pseudobulbar affect (PBA), or emotional incontinence, is a type of neurological disorder characterized by uncontrollable episodes of crying or laughing. PBA occurs secondary to a neurologic disorder or brain injury. Patients may find themselves crying uncontrollably at something that is only slightly sad, being unable to stop themselves for ...
Since pseudobulbar palsy is a syndrome associated with other diseases, treating the underlying disease may eventually reduce the symptoms of pseudobulbar palsy. [ citation needed ] Possible pharmacological interventions for pseudobulbar affect include the tricyclic antidepressants , serotonin reuptake inhibitors , and a novel approach utilizing ...
It has one drug currently approved by the Food and Drug Administration, Nuedexta, for the treatment of pseudobulbar affect. Avanir Pharmaceuticals (NAS: AVNR) is a biotechnology company developing ...
Download as PDF; Printable version; ... is a fixed-dose combination medication for the treatment of pseudobulbar affect ... and is marketed by Avanir Pharmaceuticals. [4]
Emotional disturbance (e.g. pseudobulbar affect) and cognitive and behavioural changes (e.g. problems in word fluency, decision-making, and memory) are also seen. [ 2 ] [ 6 ] There can be lower motor neuron findings (e.g. muscle wasting, muscle twitching), upper motor neuron findings (e.g. brisk reflexes, Babinski reflex , Hoffman's reflex ...
What: Shares of biotechnologist Avanir. Although we don't believe in timing the market or panicking over market movements, we do like to keep an eye on big changes -- just in case they're material ...
In contrast, pseudobulbar palsy is a clinical syndrome similar to bulbar palsy but in which the damage is located in upper motor neurons of the corticobulbar tracts in the mid-pons (i.e., in the cranial nerves IX-XII), that is the nerve cells coming down from the cerebral cortex innervating the motor nuclei in the medulla.
The growth continues for biopharmaceutical company Avanir Pharmaceuticals , which reported its 10th consecutive quarter of double-digit revenue growth despite widening losses for the quarter. For ...